Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
TG Therapeutics, Inc.
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03671590CT.gov Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies | — | Terminated | — | — | — |
NCT03379051CT.gov Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL | — | Terminated | — | — | — |
NCT03207256CT.gov Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials | — | Terminated | — | — | — |
NCT02867618CT.gov Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma | — | Terminated | — | — | — |
NCT02006485CT.gov Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies | — | Completed | — | — | — |
NCT01767766CT.gov Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Umbralisib (this asset) | TG Therapeutics, Inc. | P2 | CCC · 48 |
| Cyclosporin A | Memorial Sloan Kettering Cancer Center | P3 | BBB |
| Pegaspargase | Ciusss de L'Est de l'Île de Montréal | P4 | BBB |
| Adriamycin | National Cancer Institute (NCI) | P4 | BBB |
| Prednisolone | Mwanasha Merrill, MD | P3 | BBB |
| Entecavir | Fudan University | P4 | BBB |
| Cyclophosphamide | National Cancer Institute (NCI) | P4 | BBB |
| Rituximab | National Cancer Institute (NCI) | P4 | BBB |
| Prednisone | National Cancer Institute (NCI) | P3 | BBB |
+42 more in the Non-Hodgkin Lymphoma cohort
Other indications for Umbralisib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Marginal Zone Lymphoma | — | P2/3 | CCC · 52 |
| Follicular Lymphoma | — | P2/3 | CCC · 50 |
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P3 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Umbralisib in Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/umbralisib-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →